News|Articles|February 13, 2019

Tegsedi for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

Author(s)Drew Boxler

Tegsedi (inotersen, Akcea™ Therapeutics)

Indications: Adult Patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Dosage: 284 mg adminstered by subcutaneous injection 1x weekly

Contraindications

  • Platelet count less than 100 x 109/L (4, 5.1)

  • History of acute glomerulonephritis caused by TEGSEDI

  • Patients with a history of a hypersensitivity reaction to TEGSEDI

Click here for more prescribing information

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.


Latest CME